Agios Pharmaceuticals is discontinuing development of its oral therapy candidate, tebapivat, for people with sickle cell disease (SCD). The decision follows results from a small Phase 2 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results